We are live on ! Find out more
PCRX icon

Pacira BioSciences
PCRX

262 hedge funds and large institutions have $2.99B invested in Pacira BioSciences in 2021 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 95 increasing their positions, 84 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% more call options, than puts

Call options by funds: $6.13M | Put options by funds: $3.09M

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

13% more repeat investments, than reductions

Existing positions increased: 95 | Existing positions reduced: 84

1.49% less ownership

Funds ownership: 113.64% → 112.14% (-1.5%)

3% less funds holding

Funds holding: 270 → 262 (-8)

14% less capital invested

Capital invested by funds: $3.49B → $2.99B (-$500M)

20% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 30

Holders
262
Holders Change
-8
Holders Change %
-2.96%
% of All Funds
4.56%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.07%
New
24
Increased
95
Reduced
84
Closed
30
Calls
$6.13M
Puts
$3.09M
Net Calls
+$3.05M
Net Calls Change
-$2.42M

Top Buyers

1
Westfield Capital Management
Westfield Capital Management
Massachusetts
+$31.9M
2
Macquarie Group
Macquarie Group
Australia
+$26.8M
3
Two Sigma Advisers
Two Sigma Advisers
New York
+$19.2M
4
Two Sigma Investments
Two Sigma Investments
New York
+$17.6M
5
SPPAM
Summit Partners Public Asset Management
Massachusetts
+$14.3M

Top Sellers

1
Wells Fargo
Wells Fargo
California
-$49M
2
BlackRock
BlackRock
New York
-$32.6M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$27.6M
4
Renaissance Technologies
Renaissance Technologies
New York
-$16.1M
5
FCM
Frontier Capital Management
Massachusetts
-$14.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
276
Shelton Capital Management
Colorado
– -$200K -2,858 Closed
SFS
277
Sowell Financial Services
Arkansas
– -$122K -1,929 Closed
QT
278
Quantbot Technologies
New York
– -$123K -1,765 Closed
MWM
279
Mascoma Wealth Management
New Hampshire
– -$70K -1,000 Closed
VFA
280
Valeo Financial Advisors
Indiana
– -$45K -646 Closed
AWC
281
Abundance Wealth Counselors
Pennsylvania
– -$21K -300 Closed
SO
282
STRS Ohio
Ohio
– -$21K -300 Closed
EI
283
Ellevest Inc
New York
– -$12K -176 Closed
VCM
284
Versant Capital Management
Arizona
– -$7.15K -113 -95%
BCA
285
Berman Capital Advisors
Georgia
– -$5.51K -87 -96%
ADIM
286
Alpha DNA Investment Management
Maryland
– -$3K -55 Closed
TFO
287
Tarbox Family Office
California
– -$2K -30 Closed
JFGIW
288
Johnson Financial Group Inc (Wisconsin)
Wisconsin
– +$380 +6 New
SMA
289
Sage Mountain Advisors
Georgia
– +$506 +8 New
8 9 10 11
12

PCRX Hedge Fund Activity: Q2 2021 in Review

262 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q2 2021, worth a combined $2.99B — down 14% from $3.49B a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of PCRX and 24 opened new positions — a net loss of 6 holders — while 84 trimmed existing stakes and 95 added.

The largest buyer was Westfield Capital Management, adding an estimated $31.9M. The largest seller was Wells Fargo, cutting an estimated $49M.

  • 262 institutional investors held Pacira BioSciences (PCRX) as of Q2 2021, down from 270 in Q1 2021.
  • Funds reported $2.99B of Pacira BioSciences stock for Q2 2021, down 14% quarter-over-quarter.
  • 24 funds opened new Pacira BioSciences positions in Q2 2021 and 30 closed out, a net change of -6 holders.
  • The largest Pacira BioSciences buyer in Q2 2021 was Westfield Capital Management, an estimated $31.9M added.
  • The largest Pacira BioSciences seller in Q2 2021 was Wells Fargo, an estimated $49M sold.

Based on aggregated 13F filings for Q2 2021.